Concepts (94)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiation Oncology | 3 | 2019 | 124 | 1.200 |
Why?
|
| Sexism | 2 | 2019 | 56 | 1.160 |
Why?
|
| Physicians, Women | 1 | 2019 | 58 | 0.570 |
Why?
|
| Breast Neoplasms | 3 | 2020 | 3110 | 0.450 |
Why?
|
| Uterine Cervical Neoplasms | 4 | 2023 | 318 | 0.440 |
Why?
|
| Radiotherapy | 1 | 2016 | 320 | 0.430 |
Why?
|
| Skin | 1 | 2016 | 578 | 0.390 |
Why?
|
| Brachytherapy | 2 | 2023 | 126 | 0.340 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 3 | 2020 | 204 | 0.280 |
Why?
|
| Mastectomy | 2 | 2020 | 262 | 0.250 |
Why?
|
| Genital Neoplasms, Female | 1 | 2023 | 112 | 0.170 |
Why?
|
| Integrative Medicine | 1 | 2021 | 10 | 0.170 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2021 | 62 | 0.170 |
Why?
|
| Erythroid Precursor Cells | 1 | 2021 | 33 | 0.170 |
Why?
|
| Complementary Therapies | 1 | 2021 | 53 | 0.160 |
Why?
|
| Vaccines, DNA | 1 | 2020 | 19 | 0.160 |
Why?
|
| Human papillomavirus 18 | 1 | 2020 | 22 | 0.160 |
Why?
|
| Radiotherapy, Conformal | 1 | 2020 | 88 | 0.160 |
Why?
|
| Human papillomavirus 16 | 1 | 2020 | 45 | 0.150 |
Why?
|
| Scandinavian and Nordic Countries | 1 | 2019 | 8 | 0.150 |
Why?
|
| Women's Rights | 1 | 2019 | 8 | 0.150 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2019 | 25 | 0.150 |
Why?
|
| Safety | 1 | 2020 | 132 | 0.150 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2020 | 188 | 0.140 |
Why?
|
| Chemoradiotherapy | 1 | 2020 | 326 | 0.130 |
Why?
|
| Faculty, Medical | 1 | 2019 | 187 | 0.130 |
Why?
|
| Kinetics | 1 | 2019 | 1492 | 0.130 |
Why?
|
| Humans | 15 | 2023 | 93515 | 0.120 |
Why?
|
| Radiotherapy Dosage | 3 | 2023 | 472 | 0.120 |
Why?
|
| Patient Education as Topic | 1 | 2019 | 373 | 0.120 |
Why?
|
| Female | 10 | 2023 | 48702 | 0.120 |
Why?
|
| Radiation Injuries | 1 | 2016 | 158 | 0.110 |
Why?
|
| Feasibility Studies | 1 | 2016 | 756 | 0.110 |
Why?
|
| Physicians | 1 | 2020 | 682 | 0.100 |
Why?
|
| Internship and Residency | 1 | 2019 | 1090 | 0.080 |
Why?
|
| Risk Factors | 1 | 2020 | 5899 | 0.080 |
Why?
|
| Middle Aged | 7 | 2021 | 27573 | 0.070 |
Why?
|
| Aged, 80 and over | 3 | 2016 | 7061 | 0.060 |
Why?
|
| United States | 1 | 2019 | 7622 | 0.060 |
Why?
|
| Neoplasms | 1 | 2021 | 3169 | 0.060 |
Why?
|
| Adult | 5 | 2021 | 27918 | 0.060 |
Why?
|
| Aged | 4 | 2019 | 20434 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2016 | 9099 | 0.050 |
Why?
|
| Hodgkin Disease | 1 | 2003 | 145 | 0.050 |
Why?
|
| Bone Marrow Transplantation | 1 | 2003 | 281 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2003 | 235 | 0.050 |
Why?
|
| Male | 4 | 2019 | 44557 | 0.040 |
Why?
|
| Transplantation Conditioning | 1 | 2003 | 383 | 0.040 |
Why?
|
| Organs at Risk | 1 | 2020 | 48 | 0.040 |
Why?
|
| Neoplasm Staging | 3 | 2021 | 2017 | 0.040 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2020 | 30 | 0.040 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2020 | 33 | 0.040 |
Why?
|
| Uterus | 1 | 2021 | 227 | 0.040 |
Why?
|
| Self Care | 1 | 2021 | 167 | 0.040 |
Why?
|
| Adaptive Immunity | 1 | 2021 | 179 | 0.040 |
Why?
|
| Pain Management | 1 | 2021 | 180 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2021 | 502 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2020 | 443 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1998 | 424 | 0.030 |
Why?
|
| Prostate-Specific Antigen | 1 | 1998 | 337 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2021 | 761 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 1234 | 0.030 |
Why?
|
| Vulvar Neoplasms | 1 | 1993 | 19 | 0.020 |
Why?
|
| Ploidies | 1 | 1993 | 39 | 0.020 |
Why?
|
| S Phase | 1 | 1993 | 64 | 0.020 |
Why?
|
| Quality of Life | 1 | 2021 | 1780 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 1998 | 1264 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 1998 | 1275 | 0.020 |
Why?
|
| Survival Analysis | 3 | 2003 | 1524 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 1998 | 1173 | 0.020 |
Why?
|
| Proportional Hazards Models | 2 | 2003 | 889 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2021 | 10164 | 0.020 |
Why?
|
| Mice | 1 | 2021 | 12269 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 1998 | 1775 | 0.020 |
Why?
|
| Prognosis | 3 | 2003 | 3911 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1993 | 1077 | 0.020 |
Why?
|
| Carmustine | 1 | 2003 | 71 | 0.010 |
Why?
|
| Whole-Body Irradiation | 1 | 2003 | 70 | 0.010 |
Why?
|
| Etoposide | 1 | 2003 | 204 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2003 | 278 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 2003 | 359 | 0.010 |
Why?
|
| Animals | 1 | 2021 | 28155 | 0.010 |
Why?
|
| Disease Management | 1 | 2003 | 358 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2003 | 1723 | 0.010 |
Why?
|
| Radiotherapy, High-Energy | 1 | 1998 | 44 | 0.010 |
Why?
|
| Receptors, IgG | 1 | 1998 | 68 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 1998 | 163 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 1998 | 460 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1993 | 266 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1993 | 712 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 1993 | 504 | 0.010 |
Why?
|
| Adolescent | 1 | 2003 | 9606 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1993 | 1448 | 0.000 |
Why?
|
| Follow-Up Studies | 1 | 1993 | 3830 | 0.000 |
Why?
|